BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 7807474)

  • 1. Leuprolide acetate depot for the treatment of uterine leiomyomas. Changes in bone density, uterine volume and uterine vascular resistive index.
    Rivlin ME; Patel RB; Hess LW; Hess DB; Meeks GR
    J Reprod Med; 1994 Sep; 39(9):663-6. PubMed ID: 7807474
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term effectiveness and safety of GnRH agonist plus raloxifene administration in women with uterine leiomyomas.
    Palomba S; Orio F; Russo T; Falbo A; Cascella T; Doldo P; Nappi C; Lombardi G; Mastrantonio P; Zullo F
    Hum Reprod; 2004 Jun; 19(6):1308-14. PubMed ID: 15117890
    [TBL] [Abstract][Full Text] [Related]  

  • 3. GnRH agonist and iron versus placebo and iron in the anemic patient before surgery for leiomyomas: a randomized controlled trial. Leuprolide Acetate Study Group.
    Stovall TG; Muneyyirci-Delale O; Summitt RL; Scialli AR
    Obstet Gynecol; 1995 Jul; 86(1):65-71. PubMed ID: 7784025
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term medical therapy for leiomyomata uteri: a prospective, randomized study of leuprolide acetate depot plus either oestrogen-progestin or progestin 'add-back' for 2 years.
    Friedman AJ; Daly M; Juneau-Norcross M; Gleason R; Rein MS; LeBoff M
    Hum Reprod; 1994 Sep; 9(9):1618-25. PubMed ID: 7836510
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effects of RU 486 and leuprolide acetate on uterine artery blood flow in the fibroid uterus: a prospective, randomized study.
    Reinsch RC; Murphy AA; Morales AJ; Yen SS
    Am J Obstet Gynecol; 1994 Jun; 170(6):1623-7; discussion 1627-8. PubMed ID: 8203418
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Preoperative treatment of uterine leiomyomas: clinical findings and expression of transforming growth factor-beta3 and connective tissue growth factor.
    De Falco M; Staibano S; D'Armiento FP; Mascolo M; Salvatore G; Busiello A; Carbone IF; Pollio F; Di Lieto A
    J Soc Gynecol Investig; 2006 May; 13(4):297-303. PubMed ID: 16697947
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Estriol add-back therapy in the long-acting gonadotropin-releasing hormone agonist treatment of uterine leiomyomata.
    Nakayama H; Yano T; Sagara Y; Kikuchi A; Ando K; Wang Y; Watanabe M; Matsumi H; Osuga Y; Momoeda M; Taketani Y
    Gynecol Endocrinol; 1999 Dec; 13(6):382-9. PubMed ID: 10685331
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Short term treatment with leuprolide acetate is a successful adjunct to surgical therapy of leiomyomas of the uterus.
    Coddington CC; Brzyski R; Hansen KA; Corley DR; McIntyre-Seltman K; Jones HW
    Surg Gynecol Obstet; 1992 Jul; 175(1):57-63. PubMed ID: 1621201
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MED12 mutations in uterine leiomyomas: prediction of volume reduction by gonadotropin-releasing hormone agonists.
    Nagai K; Asano R; Sekiguchi F; Asai-Sato M; Miyagi Y; Miyagi E
    Am J Obstet Gynecol; 2023 Feb; 228(2):207.e1-207.e9. PubMed ID: 36150519
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunohistochemistry of vascular changes in leuprolide acetate-treated leiomyomas.
    Mesia AF; Gahr D; Wild M; Mittal K; Demopoulos RI
    Am J Obstet Gynecol; 1997 May; 176(5):1026-9. PubMed ID: 9166163
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Relationship between platelet-derived growth factor expression in leiomyomas and uterine volume changes after gonadotropin-releasing hormone agonist treatment.
    Di Lieto A; De Rosa G; De Falco M; Iannotti F; Staibano S; Pollio F; Scaramellino M; Salvatore G
    Hum Pathol; 2002 Feb; 33(2):220-4. PubMed ID: 11957148
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Suppression of cell proliferation and induction of apoptosis in uterine leiomyoma by gonadotropin-releasing hormone agonist (leuprolide acetate).
    Mizutani T; Sugihara A; Nakamuro K; Terada N
    J Clin Endocrinol Metab; 1998 Apr; 83(4):1253-5. PubMed ID: 9543151
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Raloxifene administration in women treated with gonadotropin-releasing hormone agonist for uterine leiomyomas: effects on bone metabolism.
    Palomba S; Orio F; Morelli M; Russo T; Pellicano M; Nappi C; Mastrantonio P; Lombardi G; Colao A; Zullo F
    J Clin Endocrinol Metab; 2002 Oct; 87(10):4476-81. PubMed ID: 12364422
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunohistochemical detection of insulin-like growth factor type I receptor and uterine volume changes in gonadotropin-releasing hormone analog-treated uterine leiomyomas.
    Di Lieto A; Iannotti F; De Falco M; Staibano S; Pollio F; Ciociola F; De Rosa G
    Am J Obstet Gynecol; 2003 Mar; 188(3):702-6. PubMed ID: 12634644
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Shrinkage effect of gonadotropin releasing hormone agonist treatment on uterine leiomyomas and t(12;14).
    Takahashi K; Kawamura N; Ishiko O; Ogita S
    Int J Oncol; 2002 Feb; 20(2):279-83. PubMed ID: 11788889
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Induced hypoestrogenism increases the arterial resistance index of leiomyomata without affecting uterine or carotid arteries.
    Spong CY; Sinow R; Renslo R; Cabus E; Rutgers J; Kletzky OA
    J Assist Reprod Genet; 1995 May; 12(5):338-41. PubMed ID: 8520200
    [No Abstract]   [Full Text] [Related]  

  • 17. Oral Gonadotropin-Releasing Hormone Antagonist Relugolix Compared With Leuprorelin Injections for Uterine Leiomyomas: A Randomized Controlled Trial.
    Osuga Y; Enya K; Kudou K; Tanimoto M; Hoshiai H
    Obstet Gynecol; 2019 Mar; 133(3):423-433. PubMed ID: 30741797
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The combined effect of a GnRH analog in premenopause plus postmenopausal estrogen deficiency for the treatment of uterine leiomyomas in perimenopausal women.
    de Aloysio D; Altieri P; Pretolani G; Romeo A; Paltrinieri F
    Gynecol Obstet Invest; 1995; 39(2):115-9. PubMed ID: 7737580
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tibolone reverses the cognitive effects caused by leuprolide acetate administration, improving mood and quality of life in patients with symptomatic uterine leiomyomas.
    Palomba S; Orio F; Falbo A; Oppedisano R; Tolino A; Zullo F
    Fertil Steril; 2008 Jul; 90(1):165-73. PubMed ID: 18001721
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of gonadotropin-releasing hormone agonists on uterine leiomyomas.
    Cramer SF
    Arch Pathol Lab Med; 1998 Dec; 122(12):1045-6. PubMed ID: 9870847
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.